Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative
17. Juni 2024 08:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis – – American Heart Association to work with champions at 15 healthcare sites to implement initiative...
Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
04. Juni 2024 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual...
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
07. Mai 2024 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities...
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
23. April 2024 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $370 - $390 million ––...
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
16. April 2024 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at...
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
02. April 2024 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Abiprubart Phase 2b trial in Sjogren’s Disease planned to initiate in 2H 2024 –– Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity –– Abiprubart development...
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
28. Februar 2024 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively – – ARCALYST 2024 net product revenue expected to be $360 - $380 million,...
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
21. Februar 2024 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, February 28, 2024...
Kiniksa Pharmaceuticals Provides Corporate Update
04. Januar 2024 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) – – ARCALYST 2024 net product revenue expected to be $360 - $380 million – – Abiprubart...
Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
02. Januar 2024 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday,...